pre-IPO PHARMA

COMPANY OVERVIEW

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 17 years' expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.


LOCATION

  • Tübingen, , Germany
  • Frankfurt, , Germany
  • Boston, MA, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Oncology

  • WEBSITE

    https://www.curevac.com/


    CAREER WEBSITE

    https://www.curevac.com/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Mar 22, 2018

    CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA


    Feb 13, 2018

    CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria


    Jan 24, 2018

    CureVac Expands Intellectual Property Position That Significantly Improves Protein Expression for Its mRNA-Based Vaccines and Therapeutics


    Jan 10, 2018

    CureVac Highlights Key 2018 Corporate Milestones and Outlook


    Jan 4, 2018

    CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics


    For More Press Releases


    Google Analytics Alternative